title: Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.
abstract: Adrenal carcinoma (ACC) is a rare neoplasm with a poor outcome. Aberrant expression of β-catenin has been found in approximatively 30% of ACC. We herein studied its effects on the growth of the human ACC cell line H295R. The cells were infected with short hairpin RNA (shRNA)-mediated silencing β-catenin. Two shRNAs used induced down-regulation of β-catenin protein levels. The expression of these shRNAs decreased cell growth and increased H295R cells in S and G2/M phases. This cytostatic effect is due to a decrease of phosphorylated MAPK and to an up-regulation expression of the cyclin-dependent kinase inhibitors p57(KIP2), p21(CIP) and p27(KIP1). In addition, the knockdown of β-catenin decreased phosphorylated Akt and increased apoptosis. Finally, loss of β-catenin was sufficient to induce the reversal of the epithelial-to-mesenchymal transition. We then transplanted these genetically modified H295R cells in Scid mice. Tumor growth suppression was achieved by the two shRNAs showing in vitro efficacy. Proliferation was not reduced in silenced tumors. In contrast, p57, p27 and p21 proteins were found expressed at high levels in silenced tumors along with an increase in apoptotic cells. These findings indicate that β-catenin loss in H295R cells inhibits tumor growth by inducing transcriptional and functional changes.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.|Commissariat à l'Energie Atomique, Institute of Life Sciences Research and Technologies, Biology of Cancer and Infection, Grenoble, France.|Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France.
authors.forename: Aude
authors.initials: A
authors.lastname: Salomon
authors.affiliation: Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.|Commissariat à l'Energie Atomique, Institute of Life Sciences Research and Technologies, Biology of Cancer and Infection, Grenoble, France.|Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France.
authors.forename: Michelle
authors.initials: M
authors.lastname: Keramidas
authors.affiliation: Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.|Commissariat à l'Energie Atomique, Institute of Life Sciences Research and Technologies, Biology of Cancer and Infection, Grenoble, France.|Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Maisin
authors.affiliation: Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.|Commissariat à l'Energie Atomique, Institute of Life Sciences Research and Technologies, Biology of Cancer and Infection, Grenoble, France.|Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France.
authors.forename: Michaël
authors.initials: M
authors.lastname: Thomas
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D018268:Adrenocortical Carcinoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics / Q000378:metabolism; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000235:genetics / Q000378:metabolism; D050761:Cyclin-Dependent Kinase Inhibitor p57 / Q000235:genetics / Q000378:metabolism; D015536:Down-Regulation; D058750:Epithelial-Mesenchymal Transition; D059565:G2 Phase Cell Cycle Checkpoints; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D006801:Humans; D016513:Mice, SCID; D010641:Phenotype; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D034622:RNA Interference; D000067492:RNAi Therapeutics; D059807:S Phase Cell Cycle Checkpoints; D015398:Signal Transduction; D013997:Time Factors; D014162:Transfection; D047368:Tumor Burden; D023041:Xenograft Model Antitumor Assays; D051176:beta Catenin / Q000235:genetics / Q000378:metabolism*
chemical_list: C493956:CDKN1A protein, human; C436291:CDKN1B protein, human; C493964:CDKN1C protein, human; C495270:CTNNB1 protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D050761:Cyclin-Dependent Kinase Inhibitor p57; D051176:beta Catenin; D050760:Cyclin-Dependent Kinase Inhibitor p27; D051057:Proto-Oncogene Proteins c-akt
keywords: adrenocortical carcinoma; epithelial-mesenchymal transition; shRNA; β-catenin
references.citation: Clin Cancer Res. 2003 Apr;9(4):1291-300
references.pmid: 12684397
references.citation: Am J Pathol. 2012 Sep;181(3):1017-33
references.pmid: 22800756
references.citation: Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24
references.pmid: 12781368
references.citation: Mol Cell Biol. 2002 Feb;22(4):1172-83
references.pmid: 11809808
references.citation: Silence. 2010 Jul 08;1(1):14
references.pmid: 20615220
references.citation: Cancer. 2006 Aug 15;107(4):864-73
references.pmid: 16832814
references.citation: Cancer Res. 2005 Sep 1;65(17):7622-7
references.pmid: 16140927
references.citation: Cell Res. 2009 Feb;19(2):156-72
references.pmid: 19153598
references.citation: J Clin Invest. 2005 Apr;115(4):978-85
references.pmid: 15761500
references.citation: Mod Pathol. 2010 Dec;23(12):1596-604
references.pmid: 20693985
references.citation: Cell. 2009 Nov 25;139(5):871-90
references.pmid: 19945376
references.citation: Genes Dev. 1997 Apr 1;11(7):847-62
references.pmid: 9106657
references.citation: J Clin Invest. 2009 Jun;119(6):1420-8
references.pmid: 19487818
references.citation: Nat Med. 1997 Sep;3(9):978-83
references.pmid: 9288723
references.citation: Neoplasia. 2007 Nov;9(11):951-9
references.pmid: 18030363
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5133-41
references.pmid: 20978149
references.citation: Oncogene. 2001 Mar 29;20(14):1688-702
references.pmid: 11313917
references.citation: J Biol Chem. 2002 Sep 6;277(36):33398-410
references.pmid: 12052822
references.citation: Science. 2000 Mar 3;287(5458):1606-9
references.pmid: 10733430
references.citation: Annu Rev Cell Dev Biol. 2004;20:781-810
references.pmid: 15473860
references.citation: Mol Ther. 2014 Jan;22(1):92-101
references.pmid: 24089139
references.citation: J Clin Endocrinol Metab. 2008 Jun;93(6):2057-62
references.pmid: 18334586
references.citation: Mol Cell Endocrinol. 1999 Jul 20;153(1-2):125-36
references.pmid: 10459860
references.citation: Genes Dev. 1999 Jun 15;13(12):1501-12
references.pmid: 10385618
references.citation: Mol Cell Endocrinol. 2009 Mar 5;300(1-2):169-74
references.pmid: 19007854
references.citation: Development. 2013 Aug;140(15):3079-93
references.pmid: 23861057
references.citation: Nature. 2004 Nov 18;432(7015):298-306
references.pmid: 15549091
references.citation: Biochem Biophys Res Commun. 2010 Jan 22;391(4):1610-5
references.pmid: 20026060
references.citation: Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11335-40
references.pmid: 10500177
references.citation: Cancer Res. 2010 Nov 1;70(21):8276-81
references.pmid: 20959480
references.citation: Biochim Biophys Acta. 2000 Jul 31;1471(1):M43-56
references.pmid: 10967424
references.citation: Annu Rev Physiol. 2011;73:413-35
references.pmid: 21054168
references.citation: Nat Rev Cancer. 2013 Jan;13(1):11-26
references.pmid: 23258168
references.citation: J Cell Physiol. 2000 Apr;183(1):18-27
references.pmid: 10699962
references.citation: Clin Cancer Res. 2011 Jan 15;17(2):328-36
references.pmid: 21088256
references.citation: Cancer Discov. 2013 Apr;3(4):406-17
references.pmid: 23358650
references.citation: J Biol Chem. 2002 Apr 5;277(14):11617-20
references.pmid: 11805123
references.citation: Hum Pathol. 1990 Mar;21(3):277-82
references.pmid: 2312105
references.citation: Nat Rev Cancer. 2003 Jan;3(1):11-22
references.pmid: 12509763
references.citation: Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):273-89
references.pmid: 19500769
references.citation: J Clin Invest. 2009 Jun;119(6):1429-37
references.pmid: 19487819
references.citation: Leukemia. 2003 Mar;17(3):590-603
references.pmid: 12646949
references.citation: Clin Cancer Res. 2009 Apr 15;15(8):2731-8
references.pmid: 19351774
references.citation: Anticancer Res. 1997 Mar-Apr;17(2B):1303-9
references.pmid: 9137490
references.citation: Cell. 1995 Aug 25;82(4):675-84
references.pmid: 7664346
references.citation: Proc Natl Acad Sci U S A. 1980 Feb;77(2):1039-43
references.pmid: 6928659
references.citation: Biochem J. 2014 Jul 1;461(1):1-13
references.pmid: 24927119
references.citation: Trends Biochem Sci. 1999 Feb;24(2):73-6
references.pmid: 10098402
references.citation: Mol Cancer Res. 2009 Dec;7(12):1902-19
references.pmid: 19934273
references.citation: Eur J Endocrinol. 2013 Jul;169(1):51-8
references.pmid: 23585556
references.citation: PLoS One. 2013;8(2):e55743
references.pmid: 23409032
references.citation: Pharm Res. 2011 Dec;28(12):2983-95
references.pmid: 22009588